bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.81 | $1M | -$3M |
| 2025 Q4 | -1.82 | $2M | -$2M |
| 2025 Q3 | -4.74 | $1M | -$2M |
| 2025 Q2 | -5.07 | $1M | -$3M |
| 2025 Q1 | -4.80 | $2M | -$2M |
| 2024 Q4 | -6.30 | $2M | -$2M |
| 2024 Q3 |
| -4.80 |
| $2M |
| -$2M |
| 2024 Q2 | -5.70 | $2M | -$2M |